Kim Lauper1, Denis Mongin2, Florenzo Iannone3, Eirik K Kristianslund4, Tore K Kvien4, Dan C Nordström5, Karel Pavelka6, Manuel Pombo-Suarez7, Ziga Rotar8, Maria J Santos9, Catalin Codreanu10, Galina Lukina11, Sara L Gale12, Markus John13, Yves Luder13, Delphine S Courvoisier2, Cem Gabay2. 1. Geneva University Hospitals, Division of Rheumatology, 1205 Geneva, Switzerland. Electronic address: kim.lauper@hcuge.ch. 2. Geneva University Hospitals, Division of Rheumatology, 1205 Geneva, Switzerland. 3. GISEA, University Hospital of Bari, Bari, Italy. 4. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. 5. ROB-FIN Helsinki University Hospital and Helsinki University, Helsinki, Finland. 6. Institut of Rheumatology, Prague and Clinic of Rheumatology Charles University, Prague, Czech Republic. 7. Rheumatology Unit, Clinical University Hospital, University of Santiago de Compostela, Santiago de Compostela, Spain. 8. BioRx.si, University Medical Centre Ljubljana, Ljubljana, Slovenia. 9. Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal. 10. Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania. 11. ARBITER, Institute of Rheumatology, Moscow, Russian Federation. 12. Genentech, South San Francisco, CA, United States. 13. F. Hoffmann-La Roche, Basel, Switzerland.
Abstract
OBJECTIVES: To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs) treated with tocilizumab (TCZ) or TNF-inhibitor (TNFi) with (-combo) or without (-mono) conventional synthetic DMARDs (csDMARDs). METHODS: Patients with RA across 7 European registries, naïve to bDMARDs who initiated treatment with TCZ or TNFi from 2009 to 2016 were included. Drug retention rate was analyzed using Kaplan-Meier and Cox models, and CDAI over time by mixed models. The proportions of patients reaching CDAI low disease activity (LDA) and remission after one year were corrected for attrition. RESULTS: 6713 TNFi-combo, 3762 TNFi-mono, 646 TCZ-combo and 384 TCZ-mono were eligible. Crude median retention was 3.67 years (95%CI 3.41-3.83) for TNFi-combo, 4.14 (3.77-4.62) for TNFi-mono, 2.98 (2.76-3.34) for TCZ-combo and 3.63 years (3.34-5.03) for TCZ-mono. After adjustment for covariates, country and year of treatment initiation stratification, hazards of discontinuation were lower for TCZ-mono (0.60, 95% CI 0.52-0.69) and TCZ-combo (0.66, 95% CI 0.54-0.81) compared to TNFi-combo. Adjusted CDAI evolution was not significantly different between groups. CDAI LDA and remission corrected for attrition were similar between TCZ with or without csDMARDs and TNFi-combo. CONCLUSION: In routine care across 7 European countries, the adjusted drug retention, adjusted CDAI over time and attrition-corrected response proportion for RA patients were similar for bio-naïve patients if treated with TNFi-combo, TCZ-combo or TCZ-mono.
OBJECTIVES: To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs) treated with tocilizumab (TCZ) or TNF-inhibitor (TNFi) with (-combo) or without (-mono) conventional synthetic DMARDs (csDMARDs). METHODS:Patients with RA across 7 European registries, naïve to bDMARDs who initiated treatment with TCZ or TNFi from 2009 to 2016 were included. Drug retention rate was analyzed using Kaplan-Meier and Cox models, and CDAI over time by mixed models. The proportions of patients reaching CDAI low disease activity (LDA) and remission after one year were corrected for attrition. RESULTS: 6713 TNFi-combo, 3762 TNFi-mono, 646 TCZ-combo and 384 TCZ-mono were eligible. Crude median retention was 3.67 years (95%CI 3.41-3.83) for TNFi-combo, 4.14 (3.77-4.62) for TNFi-mono, 2.98 (2.76-3.34) for TCZ-combo and 3.63 years (3.34-5.03) for TCZ-mono. After adjustment for covariates, country and year of treatment initiation stratification, hazards of discontinuation were lower for TCZ-mono (0.60, 95% CI 0.52-0.69) and TCZ-combo (0.66, 95% CI 0.54-0.81) compared to TNFi-combo. Adjusted CDAI evolution was not significantly different between groups. CDAI LDA and remission corrected for attrition were similar between TCZ with or without csDMARDs and TNFi-combo. CONCLUSION: In routine care across 7 European countries, the adjusted drug retention, adjusted CDAI over time and attrition-corrected response proportion for RApatients were similar for bio-naïve patients if treated with TNFi-combo, TCZ-combo or TCZ-mono.
Authors: Adrienn Markovics; Ken S Rosenthal; Katalin Mikecz; Roy E Carambula; Jason C Ciemielewski; Daniel H Zimmerman Journal: Biomedicines Date: 2021-12-26